{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-26-000653","form_type":"8-K","ticker":"LNAI","cik":"0001527728","company_name":"Lunai Bioworks Inc.","filed_at":"2026-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.424346+00:00","generated_at":"2026-05-15T00:18:17.652913+00:00","sec_items":["1.01","2.01","9.01","3.01","3.02","3.03","5.03"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lunai Bioworks completes merger to acquire CNS patent portfolio; issues $20M Series B Preferred Stock","bullets":["Acquired CNS patent portfolio via merger; issued $20M Series B Preferred Stock (no cash) to Oncotelic (62.5%) and Pelerin (37.5%).","Series B convertible at $1.50/share into up to 13.33M common shares; conversion requires stockholder approval under Nasdaq Rule 5635.","Patents cover Alzheimer's heterocyclic compounds, anti-TGF-beta agents, apomorphine, and intranasal delivery for CNS disorders.","Closed merger to address Nasdaq stockholders' equity deficiency; also needs bid price compliance by June 4, 2026; Panel decision pending.","Special meeting May 8 includes reverse split proposal for bid price compliance; conversion approval not on that ballot."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000653","json":"https://secwatch.observer/filing/0001731122-26-000653.json","markdown":"https://secwatch.observer/filing/0001731122-26-000653.md","text":"https://secwatch.observer/filing/0001731122-26-000653.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/0001731122-26-000653-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/e7595_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:18:17.652913+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c2b388994f979eee6e81c16de724aabbf9812411","claim":"Lunai Bioworks Inc. issued preferred stock for $20,000,000.","evidence_excerpt":"of the Company, the holders of the Series B Preferred Stock are entitled to a senior liquidation preference equal to the aggregate Stated Value of the Series B Preferred Stock ($20,000,000), and to the extent that, upon receipt of the Stockholder Approval, the Series B Preferred Stock will become convertible into shares of common stock at a fixed Conversion Price","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/0001731122-26-000653-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"preferred stock"},{"label":"Consideration","value":"$20,000,000"}],"fact_type":"equity_issuance"},{"claim_id":"6e7a3c22a7eda8e2ed57963799f210558dddf4fb","claim":"Lunai Bioworks Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"April 20, 2026, the Company received notice from the Panel (in the “Decision”) that it had until April 27, 2026, to regain compliance with the $2.5 million equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “S","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/0001731122-26-000653-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"d6c4359ecb2a24a812b6e2ce4bc7887dc248fd12","claim":"Lunai Bioworks Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"April 20, 2026, the Company received notice from the Panel (in the “Decision”) that it had until April 27, 2026, to regain compliance with the $2.5 million equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “S","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/0001731122-26-000653-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"7a51f34b6207f458258129b5d4c42de89ad98343","claim":"Lunai Bioworks Inc. completed an acquisition involving Neurobridge IP Holdings Incorporated for $20,000,000 aggregate stated value of Series B Convertible Preferred Stock (closed 2026-05-01).","evidence_excerpt":"nto an Agreement and Plan of Merger (the “Merger Agreement”) with Neurobridge IP Holdings Incorporated, a Delaware corporation (“Holdings”), Lunai Bioworks IP, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/0001731122-26-000653-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Neurobridge IP Holdings Incorporated"},{"label":"Consideration","value":"$20,000,000 aggregate stated value of Series B Convertible Preferred Stock"},{"label":"Closing","value":"2026-05-01"}],"fact_type":"ma_transaction"},{"claim_id":"e6cdf9866aaad8efccb1216b5ca8523696f0862c","claim":"Lunai Bioworks Inc. entered into Merger Agreement (effective 2026-05-01).","evidence_excerpt":"The foregoing description of the Merger Agreement is a summary only and is qualified in its entirety by reference to the full text of the Merger Agreement, a copy of which is filed as Exhibit 2.1 to this Current","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/0001731122-26-000653-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Effective","value":"2026-05-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}